Global Hypertrophic Cardiomyopathy Therapeutics Market Size (2024 - 2029)

Hypertrophic Cardiomyopathy Therapeutics Market Analysis

The Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow at a CAGR of 1.8% over the forecast period (2022-2027).

Covid-19 has a considerable effect on all major organ systems. Due to the rising number of cases of Covid-19 in the initial stages of the pandemic, all hospitals around the world canceled medical visits and the target population remained indoors fearing the infection. However, the underlying cardiac disease, including heart failure (HF), is associated with increased SARS-CoV-2-related mortality. Thus, the risk of hypertrophic cardiomyopathy (HCM) increased during the pandemic. The research and developments increased for the development of advanced therapeutics for the treatment of HCM patients infected with Covid-19. An international multicenter study was conducted, and the results were published in the article 'Impact of SARS-Cov-2 Infection in Patients with Hypertrophic Cardiomyopathy: Results of an International Multicentre Registry' in June 2022. As per the study results, 1/4th of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Additionally, age and cardiac features related to HCM showed an increased risk of mortality. Thus, this generated demand for the development of drugs of therapies for patient survival during the pandemic. Therefore, the pandemic is predicted to significantly impact the market studied.

Factors such as the rise in obesity and sedentary lifestyle population coupled with new product development for targeted cardiac disorders are expected to positively impact the market growth.

The market is driven primarily by the global burden of obesity and the sedentary lifestyle of the population. For instance, the data updated by World Health Organization (WHO) in June 2021 shows that obesity has increased globally, and it has tripled in the past two decades. In addition, the World Population Review's survey 'Obesity Rates by Country 2022' results show that about 13% of adults are obese and about 39% of adults are overweight globally. As per the article 'Clinical Significance of Overweight in Patients with Hypertrophic Cardiomyopathy' published in October 2021, overweight patients were associated with more heart failure (HF) rehospitalization in HCM patients and being overweight was an independent determinant of major adverse cardiovascular and cerebral events (MACCE) in HCM patients. Thus, the burden of obesity and overweight coupled with the risk of heart failure among hypertrophic cardiomyopathy (HCM) patients with obesity demands the availability of therapeutics for treatment. Thereby driving the market growth.

Additionally, the data updated for 'Hypertrophic Cardiomyopathy' by the 'National Library of Medicine' in June 2022, the prevalence of HCM in the general population around the world is 0.2%, as determined from echocardiographic studies. Additionally, as per the source mentioned above, morphologic evidence is found in approximately 25% of first-degree relatives of patients with HCM. Thus, the high burden of the disease is demanding therapeutics for the treatment and patient survival. Therefore, it is expected to propel the studied market growth over the forecast period.

Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the technological advancement in devices is one of the major factors that is anticipated to hinder the market growth.

Hypertrophic Cardiomyopathy Therapeutics Industry Segmentation

As per the scope of this report, hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused by a mutation in sarcomere protein genes that encodes for the contractile machinery of the heart. The Hypertrophic Cardiomyopathy Therapeutics Market is segmented by Drug Class (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.